ClinicalTrials.gg
Status unknownNCT03330587Updated Nov 18, 2023

Living Alone in Old Age With Cognitive Impairment

An observational study in Living Alone, Alzheimer Disease and Mild Cognitive Impairment, sponsored by University of California, San Francisco. Status unknown at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by University of California, San Francisco · Observational

The sponsor has not verified this record recently (last verified Nov 2023), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
60
Ages
55 Years and older
Sex
All
01

Study summary

The purpose of this study is to better understand the experience of living alone in older age with cognitive impairment.

We recruit adults 55+ living alone with cognitive impairment such as Alzheimer's disease or mild cognitive impairment.

This study investigates the priorities and concerns of older adults living alone with cognitive impairment. Participants are interviewed 5 times for one hour in their homes within 3 months at a time that works for them.

Read the detailed description

The purpose of this study is to better understand the experience of living alone in older age with cognitive impairment. This knowledge is important to design programs that are appropriate. Dr. Elena Portacolone, an Assistant Professor from the Institute of Health and Aging is the study researcher.

Study participants are interviewed by Elena at a time and place convenient to them, usually their home. Interviews are audio recorded and last around one hour. Study participants are interviewed five times within 3 months.

After the interview, a transcriptionist will type into a computer the recording and will remove personal names. The sound recording will then be destroyed.

Participants can stop being in the study at any time.

02

Conditions studied

  • Living Alone
  • Alzheimer Disease
  • Mild Cognitive Impairment
03

In context

Alzheimer Disease

3,765 studies on the registry are indexed under Alzheimer Disease; 881 are open to participants now.

This study's planned enrollment of 60 is below the median of 200 across 780 observational studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,164 studies on the registry; 368 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 199 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Persons over 55 years of age living alone and having a medical diagnosis of Alzheimer's disease or mild cognitive impairment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Living alone
  • Medical diagnosis of Alzheimer's disease or mild cognitive impairment

Exclusion criteria

Exclusion Criteria:

  • Living in nursing homes, assistive living facilities.
  • Alcohol abuse
05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Ethnographic interviews

    Questions that follow the train of thought of study participants

    Time frame: One hour

07

Study locations

1 site
  • Institute for Health & Aging
    San Francisco, California 94705, United States
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03330587
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Mar 1, 2016
Primary completion
Feb 20, 2024 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Nov 18, 2023

Study contacts

Elena Portacolone, PhD MPH MBA
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion